Cardiogen
Also known as: Heart bioregulator, AEDR
Cardiogen (also called Heart bioregulator or AEDR) is a khavinson bioregulator. Cardiogen is Ala-Glu-Asp-Arg, a synthetic tetrapeptide in the Khavinson series associated with cardiac tissue. As with the rest of that series the proposed mechanism is direct interaction of the short peptide with promoter regions of DNA in the nucleus, modulating transcription of genes relevant to the target tissue — here cardiomyocyte protein synthesis.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- Low molecular weight peptide fraction
- Half-life
- Not established (limited PK data; primarily research context)
- FDA status
- Not Approved
- Administration Route
- Oral (capsule) or Subcutaneous in research contexts
- Frequency
- Once daily (typical research pattern)
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
- Targets
- Cardiomyocytes (proposed)
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Dec 2025 and May 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 5
- Listed offers
- 5
- Median price per mg
- $2.50/mg
- Typical $2.20–$3.00/mg
Research summary
Short peptide sold as a cardiac bioregulator in the Khavinson series. No FDA approval; evidence is historical Russian literature.
Peptide Library's Cardiogen profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- 5-20 mg daily (research context; not clinically established)
- Frequency
- Once daily (typical research pattern)
- Cycle
- Common research cycles 10-30 days; varies by protocol
- Administration Route
- Oral (capsule) or Subcutaneous in research contexts
- Reconstitution Guide
- Reconstitute with bacteriostatic water if lyophilized (research only)
- Injection Sites
- Abdomen (subQ)
- Concentration Example
- 10 mg vial reconstituted with 2 mL = 5 mg/mL
- Timing Notes
- Often administered in the morning
- Expected Onset
- Variable; gene expression changes proposed over weeks
May vary by vendor concentration and protocol.
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. Cardiogen is queued for dosage evidence review.
Compare reported doses across the whole libraryHow to reconstitute Cardiogen
- Check the vial size and diluent volume. The profile example for Cardiogen is: Reconstitute with bacteriostatic water if lyophilized (research only).
- Swab both vial stoppers and draw the bacteriostatic water into a sterile syringe.
- Add the water slowly down the inside wall of the peptide vial so it does not jet onto the powder, then swirl gently until the solution is clear. Do not shake.
- Record the resulting concentration: 10 mg vial reconstituted with 2 mL = 5 mg/mL.
- Label the vial with the date and concentration, refrigerate it (see Storage & stability below), and use the calculator preset to convert a oral (capsule) or subcutaneous in research contexts dose in mcg into syringe units.
Sequence & molecular data
| Amino acid sequence | Short peptide complex (exact proprietary sequences not publicly standardized) |
|---|---|
| Molecular formula | Varies (short peptide fraction complex) |
| Molecular weight | Low molecular weight peptide fraction |
| Half-life | Not established (limited PK data; primarily research context) |
| Appearance | White lyophilized powder |
| Formulation | Lyophilized Powder |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Cardiogen is Ala-Glu-Asp-Arg, a synthetic tetrapeptide in the Khavinson series associated with cardiac tissue. As with the rest of that series the proposed mechanism is direct interaction of the short peptide with promoter regions of DNA in the nucleus, modulating transcription of genes relevant to the target tissue — here cardiomyocyte protein synthesis. The supporting literature is principally cell-culture and cytogenetic work from a single group, published largely in Russian-language journals, and has not been replicated in contemporary randomised controlled trials. No specific receptor or characterised signalling pathway has been demonstrated.
Origin
Synthetic short peptide bioregulator.
Targets
Studies
- [Extracorporeal membrane oxygenation in intensive care unit]
- Cardiogenetics and uncertainty: Evaluation of professional vulnerability in France
- [Cardiomyopathy and ion channel diseases registry: the Szeged CardioGen Registry]
- [Experimental model for cardiogenic shock with pericardial tamponade]
- An Analysis of 3 Common CardioGen-82 82Rb Infusion System Injection Methods and Their Impact on Clinical Volume and Image Counts
Regulatory & research status
Cardiogen is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
Benefits
Cardiogen side effects
Side Effects
- Not well characterized
Stacking
Common stacking partners
Combinations that include Cardiogen, with the proposed rationale, an evidence grade and what is not established, are catalogued in the peptide stacks directory.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Cardiogen: frequently asked questions
What is Cardiogen?
Short peptide sold as a cardiac bioregulator in the Khavinson series. No FDA approval; evidence is historical Russian literature.
How does Cardiogen work?
Cardiogen is Ala-Glu-Asp-Arg, a synthetic tetrapeptide in the Khavinson series associated with cardiac tissue. As with the rest of that series the proposed mechanism is direct interaction of the short peptide with promoter regions of DNA in the nucleus, modulating transcription of genes relevant to the target tissue — here cardiomyocyte protein synthesis.
Is Cardiogen FDA approved?
No. Cardiogen is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of Cardiogen?
Reported half-life for Cardiogen is Not established (limited PK data; primarily research context). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
What is the amino acid sequence of Cardiogen?
Cardiogen has the sequence Short peptide complex (exact proprietary sequences not publicly standardized). Its molecular formula is Varies (short peptide fraction complex).
What peptides are similar to Cardiogen?
Compounds most often compared with Cardiogen include Bonomarlot, Bronchogen, Cartalax and Cerluten. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- [Extracorporeal membrane oxygenation in intensive care unit] — Orv Hetil, 2021External reference
- Cardiogenetics and uncertainty: Evaluation of professional vulnerability in France — Eur J Med Genet, 2025External reference
- [Cardiomyopathy and ion channel diseases registry: the Szeged CardioGen Registry] — Orv Hetil, 2017External reference
- [Experimental model for cardiogenic shock with pericardial tamponade] — Magy Seb, 2017External reference
- An Analysis of 3 Common CardioGen-82 82Rb Infusion System Injection Methods and Their Impact on Clinical Volume and Image Counts — J Nucl Med Technol, 2015External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Cardiogen profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Cardiogen research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →